Загрузка...
Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results
OBJECTIVE: Treatment with the anti-CD20 monoclonal antibody (mAb) rituximab is effective in rheumatoid arthritis (RA). Marked depletion of circulating B cells, seen in almost all patients, does not correlate with efficacy. The potential synovial immunomodulatory effects of rituximab have not been fu...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2007
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2754142/ https://ncbi.nlm.nih.gov/pubmed/17644541 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2007.074229 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|